Overall Share of Ocrevus Remains Stable Among Recent New Start Patients, Yet Genentech’s Efforts to Increase First-Line Use Appears to be Paying Off in the Dominant Relapsing-Remitting Multiple Sclerosis Subgroup
Ocrevus cedes substantial ground to off-label glatiramer acetate agents (particularly generics) in the first-line primary progressive multiple sclerosis subgroup, due to a desire for favorable tolerability and pressure from payers, with little hope of redemption coming from potential first switches among these patients, according to Spherix Global Insights’ most recent patient chart audit EXTON, Pa., […]
AbbVie’s Rinvoq continues march with NICE nod in rheumatoid arthritis
From: FiercePharma By: Kyle Blankenship AbbVie’s Rinvoq Continues March with NICE Nod in Rheumatoid Arthritis In December, a rheumatologist survey conducted by Spherix Global Insights showed about half of 100 physicians would prescribe Rinvoq over other JAK inhibitors, specifically citing AbbVie’s “stewardship” of the drug as a positive for prescribing, Piper analyst Christopher Raymond […]
Amgen/Novartis’ Aimovig Label Revision and Teva’s Ajovy Autoinjector Delay Clear the Way for Continued Growth of Eli Lilly’s Emgality in the US Migraine Prevention Market, According to Spherix Global Insights
Neurologists and migraine specialists believe that a potential dual acute and preventive migraine indication for Lundbeck’s eptinezumab and Biohaven’s rimegepant could be influential in differentiating the pipeline agents from Allergan’s atogepant and the currently marketed CGRP therapies EXTON, Pa., December 18, 2019 ― Eli Lilly’s Emgality, the third anti-calcitonin gene-related peptide (CGRP) therapy to the […]
Lilly Launches Real-World Study to Benchmark Emgality Against Migraine Rivals
From: Fierce Pharma By: Eric Sagonowsky Lilly Launches Real-World Study to Benchmark Emgality Against Migraine Rivals Eli Lilly’s CGRP migraine prevention med Emgality trailed its rivals onto the market, but it’s been a force in the dogfight for market share. Now, in an effort to learn more about how […]
Promising Early Launch Metrics for AbbVie’s Rinvoq (upadacitinib) to Help JAK Inhibitors Solidify Their Position as Second-Line Leaders in Rheumatoid Arthritis, According to Spherix Global Insights
As IL-6 inhibitor use in second- or later-line biologic/JAK therapy in RA declines and TNF class share remains flat, the introduction and positive early readout of the third JAK to market bodes well for the JAK inhibitor class. EXTON, Pa., December 16, 2019 /PRNewswire/ — Spherix examined the charts of 1,021 rheumatoid arthritis (RA) patients recently […]
Neurologists Anticipate Overall Expansion of the Fumarate Class Following the US Launch of Biogen’s Vumerity for Treatment in Multiple Sclerosis, According to Spherix Global Insights
While neurologists are eager to believe that Vumerity will provide a superior tolerability profile over Biogen’s own Tecfidera, increasing first-line use of Genzyme’s Aubagio, Novartis’ Mayzent, and Genentech’s Ocrevus could present additional competitive pressure in the crucial new start patient segment EXTON, Pa., December 10, 2019 ― Biogen’s Vumerity (diroximel fumarate), a monomethyl fumarate prodrug, […]
Pro-AbbVie Bias May be Driving Rheumatologist Confidence in Newcomer Rinvoq: Analyst
From: FiercePharma By: Kyle Blankenship Pro-AbbVie Bias May be Driving Rheumatologist Confidence in Newcomer Rinvoq: Analyst Between AbbVie’s two newly approved blockbusters-in-waiting, psoriasis med Skyrizi’s booming sales have drawn some analysts’ eyes away from highly-touted rheumatoid arthritis drug Rinvoq. But among physicians, Rinvoq is becoming a darling, one analyst […]
Janssen’s INVOKANA (canagliflozin) Gets Boost Over Competitors with FDA Approval for Diabetic Kidney Disease and a Newly Minted Collaboration with Renal Giant, Vifor Pharma
According to Spherix Global Insights, the approval of INVOKANA was highly anticipated among nephrologists and may present a paradigm shift in the way patients with type 2 diabetes and chronic kidney disease (CKD) are treated in the future EXTON, Pa., November 25, 2019 – It is well-documented that nearly half of patients with type 2 […]
Ocrevus Top Choice of US Neurologists for Active SPMS, But Mayzent and Mavenclad Gaining Interest, Report Says
From: Multiple Sclerosis News Today By: Ana Pena, PHD Ocrevus Top Choice of US Neurologists for Active SPMS, But Mayzent and Mavenclad Gaining Interest, Report Says Genentech‘s Ocrevus (ocrelizumab) continues to be the most prescribed medication to reduce inflammatory disease in people with active secondary progressive multiple sclerosis (SPMS) among U.S. neurologists, even though Novartis’ Mayzent (siponimod) and EMD Serono’s Mavenclad (cladribine) were […]
Opportunity for EMD Serono’s Mavenclad is Growing in the Relapsing-Remitting Multiple Sclerosis Segment of the Canada Market, Although Increasingly Deferred Treatment Algorithm Positioning Is a Threat That Could Benefit Roche’s Ocrevus and Novartis’ Gilenya
With neurologists eagerly waiting for approval of Mayzent and interest growing in ofatumumab, Novartis is seen as a highly credible company with the potential to offer a diverse multiple sclerosis portfolio, according to Spherix Global Insights EXTON, Pa., November 19, 2019 ― Once approved by Health Canada and accessible on provincial drug formularies, the Canadian […]
